Wedbush Starts Intellia Therapeutics (NTLA) at Outperform

Wedbush initiates coverage on Intellia Therapeutics (NASDAQ: NTLA) with a Outperform rating and a price target of $38.00.

Analyst David Nierengarten commented, "Intellia represents an opportunity to invest in a broadlyapplicable, revolutionary technology with what is likely to be the dominant intellectual property in the space, in our opinion."

He added, "Intellia’s platform could transform the gene therapy landscape. Based on the recent breakthrough discoveries of the genome editing applications of the Crispr/Cas9 system, NTLA’s platform could be applied to develop potentially curative therapies for a broad range of disorders. With advantages in specificity and ease of development over prior gene editing technologies, and providing greater functionality than traditional gene therapy approaches, we see Crispr/Cas9 as the best gene-editing tool available."

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $29.50 yesterday.

You May Also Be Interested In

• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• KKR Real Estate Financial Trust (KREF) PT Lowered to $12 at JMP Securities
• Owens Corning (OC) PT Raised to $172 at Evercore ISI